Osteoblasts protect AML cells from SDF-1-induced apoptosis

Journal of Cellular Biochemistry

Volumn 115, Issue 6, 2014, Pages 1128-1137

  Kremer, Kimberly N ^a   Dudakovic, Amel ^b   McGee Lawrence, Meghan E ^b   Philips, Rachael L ^a   Hess, Allan D ^c   Smith, B Douglas ^c   Van Wijnen, Andre J ^b,d   Karp, Judith E ^c   Kaufmann, Scott H ^a,b   Westendorf, Jennifer J ^b,d   Hedin, Karen E ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Mayo Clinic College of Medicine   (United States)

Author keywords

AML; APOPTOSIS; CXCL12; CXCR4; MESENCHYMAL; OSTEOBLAST; SDF 1

Indexed keywords

ALIZARIN; ALKALINE PHOSPHATASE; ASCORBIC ACID; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; GLYCEROPHOSPHATE; HYDROCORTISONE; MESSENGER RNA; OSTEOCALCIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; PHOTOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL CONTACT; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRAIN U937; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA RELAPSE; MESENCHYME CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ACUTE DISEASE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINE; COCULTURE; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; U937 CELL LINE;

ACUTE DISEASE; ALKALINE PHOSPHATASE; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID; LUMINESCENT PROTEINS; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCALCIN; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; U937 CELLS;

EID: 84907422946     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24755     Document Type: Article

References (30)

1. Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT,. 2004. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89: 391-402.
2. Burgers TA, Williams BO,. 2013. Regulation of Wnt/beta-catenin signaling within and from osteocytes. Bone 54: 244-249.
3. Cao H, Oteiza A, Nilsson SK,. 2013. Understanding the role of the microenvironment during definitive hemopoietic development. Exp Hematol 41: 761-768.
4. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I,. 2006. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 20: 161-171.
5. De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F, Salles JP, Demur C, Allouche M, Payrastre B, Manenti S, Ysebaert L,. 2006. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113-3122.
6. Doan PL, Chute JP,. 2012. The vascular niche: Home for normal and malignant hematopoietic stem cells. Leukemia 26: 54-62.
7. Dong-Feng Z, Ting L, Yong Z, Cheng C, Xi Z, Pei-Yan K,. 2013. The TPO/c-MPL pathway in the bone marrow may protect leukemia cells from chemotherapy in AML patients. Pathol Oncol Res.
8. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP,. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4: 72-77.
9. Ehninger A, Trumpp A,. 2011. The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in. J Exp Med 208: 421-428.
10. Emadi A, Karp JE,. 2012. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics 13: 1257-1269.
11. English D, Andersen BR,. 1974. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 5: 249-252.
12. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD,. 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321.
13. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D,. 2007. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117: 1049-1057.
14. Jensen ED, Gopalakrishnan R, Westendorf JJ,. 2010. Regulation of gene expression in osteoblasts. Biofactors 36: 25-32.
15. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M,. 2002. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16: 1713-1724.
16. Konopleva M, Tabe Y, Zeng Z, Andreeff M,. 2009. Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Updat 12: 103-113.
17. Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, Smith BD, Rodriguez-Ramirez C, Karp JE, Kaufmann SH, Hedin KE,. 2013. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem 288: 22899-22914.
18. Kumagai M, Manabe A, Pui CH, Behm FG, Raimondi SC, Hancock ML, Mahmoud H, Crist WM, Campana D,. 1996. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 97: 755-760.
19. Kumar A, Humphreys TD, Kremer KN, Bramati PS, Bradfield L, Edgar CE, Hedin KE,. 2006. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 25: 213-224.
20. Kumar A, Kremer KN, Dominguez D, Tadi M, Hedin KE,. 2011. Galpha13 and Rho mediate endosomal trafficking of CXCR4 into Rab11+ vesicles upon stromal cell-derived factor-1 stimulation. J Immunol 186: 951-958.
21. Kwong-Lam F, Chi-Fung CG,. 2013. Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment. Exp Hematol Oncol 2: 11.
22. Levesque JP, Helwani FM, Winkler IG,. 2010. The endosteal "osteoblastic" niche and its role in hematopoietic stem cell homing and mobilization. Leukemia 24: 1979-1992.
23. Liersch R, Gerss J, Schliemann C, Bayer M, Schwoppe C, Biermann C, Appelmann I, Kessler T, Lowenberg B, Buchner T, Hiddemann W, Muller-Tidow C, Berdel WE, Mesters R,. 2012. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood 119: 5215-5220.
24. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, Campana D,. 2003. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 120: 846-849.
25. Moore KA, Ema H, Lemischka IR,. 1997. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 89: 4337-4347.
26. Nwabo Kamdje AH, Krampera M,. 2011. Notch signaling in acute lymphoblastic leukemia: Any role for stromal microenvironment ? Blood 118: 6506-6514.
27. Singbrant S, Askmyr M, Purton LE, Walkley CR,. 2011. Defining the hematopoietic stem cell niche: The chicken and the egg conundrum. J Cell Biochem 112: 1486-1490.
28. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V,. 1992. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130: 1318-1324.
29. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT,. 1999. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 14: 893-903.
30. Yang Y, Mallampati S, Sun B, Zhang J, Kim SB, Lee JS, Gong Y, Cai Z, Sun X,. 2013. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett 333: 9-17.